Nursing practice questions with comprehensive rationales
NurseDive Free Nursing Practice Question
The client’s blood glucose level is 220 mg/dL. The client is about to eat breakfast. The prescribed sliding scale indicates that 4 units of insulin lispro (Humalog) be given subcutaneously at 7:30 am. At what time is the client most at risk for hypoglycemia?
A. Today at 8:30 am
Insulin lispro, a rapid-acting insulin, peaks 1-2 hours after administration (around 8:30-9:30 am for a 7:30 am dose). This peak coincides with maximum glucose-lowering effect, increasing hypoglycemia risk, especially if breakfast is inadequate or delayed. This time is the most likely for low blood sugar due to insulin’s pharmacodynamics.
B. Today at 7:45 am
At 7:45 am, insulin lispro is just beginning to act (onset 15-30 minutes), and breakfast is likely being consumed, providing glucose to counter insulin’s effect. Hypoglycemia risk is lower than at peak action (1-2 hours), making this time less critical for hypoglycemia monitoring.
C. Today at 12:30 pm
By 12:30 pm, insulin lispro’s effect (duration 3-5 hours) is waning, and glucose from breakfast is metabolized. Hypoglycemia risk is lower unless additional insulin or activity occurs. This time is less likely for hypoglycemia compared to the peak action period around 8:30 am.
D. Tomorrow at 6:30 am
Tomorrow at 6:30 am is beyond insulin lispro’s duration of action (3-5 hours). Hypoglycemia risk from the 7:30 am dose is negligible 23 hours later, as insulin is cleared. This time is irrelevant to the dose’s effect, making it the least likely for hypoglycemia.
This question is an excerpt from Nurse Dive's nursing test bank - Pathophamacology Proctored Exam (Examplify). Take the full exam now
Full Explanation
Choice A reason: Insulin lispro, a rapid-acting insulin, peaks 1-2 hours after administration (around 8:30-9:30 am for a 7:30 am dose). This peak coincides with maximum glucose-lowering effect, increasing hypoglycemia risk, especially if breakfast is inadequate or delayed. This time is the most likely for low blood sugar due to insulin’s pharmacodynamics.
Choice B reason: At 7:45 am, insulin lispro is just beginning to act (onset 15-30 minutes), and breakfast is likely being consumed, providing glucose to counter insulin’s effect. Hypoglycemia risk is lower than at peak action (1-2 hours), making this time less critical for hypoglycemia monitoring.
Choice C reason: By 12:30 pm, insulin lispro’s effect (duration 3-5 hours) is waning, and glucose from breakfast is metabolized. Hypoglycemia risk is lower unless additional insulin or activity occurs. This time is less likely for hypoglycemia compared to the peak action period around 8:30 am.
Choice D reason: Tomorrow at 6:30 am is beyond insulin lispro’s duration of action (3-5 hours). Hypoglycemia risk from the 7:30 am dose is negligible 23 hours later, as insulin is cleared. This time is irrelevant to the dose’s effect, making it the least likely for hypoglycemia.
Similar Questions
What is the common mechanism of action for all antidepressants, whether they are SSRIs or tricyclics?
A. Increase efficacy of GABA in limbic system and cortex
GABA, an inhibitory neurotransmitter, is not the primary target of antidepressants like SSRIs or tricyclics. These drugs focus on monoamines (serotonin, norepinephrine). GABAergic drugs, like benzodiazepines, treat anxiety, not depression. This statement is inaccurate, as antidepressants do not enhance GABA efficacy in the limbic system or cortex.
B. Block reuptake of norepinephrine and/or serotonin
SSRIs and tricyclics block reuptake of serotonin and/or norepinephrine in the synaptic cleft, increasing their availability to stimulate postsynaptic receptors. This enhances monoamine signaling, alleviating depressive symptoms. This statement is accurate, as reuptake inhibition is the shared mechanism across these antidepressant classes, targeting mood-regulating neurotransmitters.
C. Antagonize dopamine receptors on postsynaptic membrane
Dopamine receptor antagonism is not a mechanism of antidepressants but is associated with antipsychotics like haloperidol. While some antidepressants indirectly affect dopamine, it is not their primary action. This statement is inaccurate, as SSRIs and tricyclics focus on serotonin and norepinephrine, not dopamine receptor blockade.
D. Antagonize serotonin receptors on postsynaptic membrane
Antagonizing serotonin receptors would reduce serotonin signaling, counteracting antidepressant effects. SSRIs and tricyclics increase serotonin availability via reuptake inhibition, not receptor blockade. This statement is inaccurate, as blocking serotonin receptors is not a mechanism of action for these depression treatments.
Full Explanation
Choice A reason: GABA, an inhibitory neurotransmitter, is not the primary target of antidepressants like SSRIs or tricyclics. These drugs focus on monoamines (serotonin, norepinephrine). GABAergic drugs, like benzodiazepines, treat anxiety, not depression. This statement is inaccurate, as antidepressants do not enhance GABA efficacy in the limbic system or cortex.
Choice B reason: SSRIs and tricyclics block reuptake of serotonin and/or norepinephrine in the synaptic cleft, increasing their availability to stimulate postsynaptic receptors. This enhances monoamine signaling, alleviating depressive symptoms. This statement is accurate, as reuptake inhibition is the shared mechanism across these antidepressant classes, targeting mood-regulating neurotransmitters.
Choice C reason: Dopamine receptor antagonism is not a mechanism of antidepressants but is associated with antipsychotics like haloperidol. While some antidepressants indirectly affect dopamine, it is not their primary action. This statement is inaccurate, as SSRIs and tricyclics focus on serotonin and norepinephrine, not dopamine receptor blockade.
Choice D reason: Antagonizing serotonin receptors would reduce serotonin signaling, counteracting antidepressant effects. SSRIs and tricyclics increase serotonin availability via reuptake inhibition, not receptor blockade. This statement is inaccurate, as blocking serotonin receptors is not a mechanism of action for these depression treatments.
The nurse is teaching a client about their medications for a psychological disorder. Which statement should not be included in the client education?
A. Renal disease may impact drug choice and dose in some clients
Renal disease affects drug clearance, particularly for psychopharmacological medications like lithium, which is renally excreted. Impaired renal function can lead to toxicity, necessitating dose adjustments or alternative drugs. This statement is accurate, as renal function is critical in tailoring psychotropic therapy to ensure safety and efficacy.
B. These medications have the risk for cytochrome P450 interactions that impact the action of the medication
Many psychopharmacological drugs, like SSRIs, are metabolized by cytochrome P450 enzymes, leading to potential drug interactions. Inhibitors or inducers of these enzymes can alter medication levels, affecting efficacy or toxicity. This statement is accurate, as P450 interactions are a key consideration in psychotropic prescribing.
C. Psychopharmacological medications have similar dosing across all age groups
Psychopharmacological dosing varies significantly across age groups. Elderly patients often require lower doses due to slower metabolism and higher sensitivity, while children’s doses are weight-based. This statement is inaccurate, as age-specific dosing adjustments are essential to prevent adverse effects and ensure therapeutic efficacy.
D. Hepatic disease can impact dose
Hepatic disease impacts drug metabolism, particularly for psychotropics like antipsychotics or SSRIs, which are hepatically cleared. Liver dysfunction can increase drug levels, risking toxicity, requiring dose adjustments. This statement is accurate, as hepatic function is a critical factor in psychopharmacological dosing and safety.
Full Explanation
Choice A reason: Renal disease affects drug clearance, particularly for psychopharmacological medications like lithium, which is renally excreted. Impaired renal function can lead to toxicity, necessitating dose adjustments or alternative drugs. This statement is accurate, as renal function is critical in tailoring psychotropic therapy to ensure safety and efficacy.
Choice B reason: Many psychopharmacological drugs, like SSRIs, are metabolized by cytochrome P450 enzymes, leading to potential drug interactions. Inhibitors or inducers of these enzymes can alter medication levels, affecting efficacy or toxicity. This statement is accurate, as P450 interactions are a key consideration in psychotropic prescribing.
Choice C reason: Psychopharmacological dosing varies significantly across age groups. Elderly patients often require lower doses due to slower metabolism and higher sensitivity, while children’s doses are weight-based. This statement is inaccurate, as age-specific dosing adjustments are essential to prevent adverse effects and ensure therapeutic efficacy.
Choice D reason: Hepatic disease impacts drug metabolism, particularly for psychotropics like antipsychotics or SSRIs, which are hepatically cleared. Liver dysfunction can increase drug levels, risking toxicity, requiring dose adjustments. This statement is accurate, as hepatic function is a critical factor in psychopharmacological dosing and safety.
Which statement about monoamine oxidase inhibitors is inaccurate?
A. The client should be careful with their diet since some foods cause adverse reactions
Monoamine oxidase inhibitors (MAOIs) require dietary restrictions to avoid tyramine-rich foods (e.g., aged cheese), which can cause hypertensive crisis by increasing norepinephrine release. MAOIs inhibit monoamine breakdown, amplifying tyramine’s effects. This statement is accurate, as dietary caution is critical to prevent serious adverse reactions.
B. Clients experience immediate improvement in symptoms
MAOIs, like phenelzine, take 2-6 weeks to improve depressive symptoms by increasing monoamine levels (serotonin, norepinephrine, dopamine). Immediate improvement does not occur due to gradual synaptic changes. This statement is inaccurate, as the delayed onset is a key characteristic of MAOIs, similar to other antidepressants.
C. These drugs are used when newer drugs have not been effective
MAOIs are reserved for treatment-resistant depression when newer drugs like SSRIs fail, due to their side effect profile and dietary restrictions. They effectively increase monoamine availability but are less preferred due to safety concerns. This statement is accurate, reflecting their role in refractory cases.
D. There are some drug-to-drug interactions that can contribute to hypertensive crisis
MAOIs can cause hypertensive crisis via drug interactions (e.g., with SSRIs or sympathomimetics), as they inhibit monoamine breakdown, leading to excessive norepinephrine. This can result in severe blood pressure elevation. This statement is accurate, as drug interactions are a significant risk with MAOI therapy.
Full Explanation
Choice A reason: Monoamine oxidase inhibitors (MAOIs) require dietary restrictions to avoid tyramine-rich foods (e.g., aged cheese), which can cause hypertensive crisis by increasing norepinephrine release. MAOIs inhibit monoamine breakdown, amplifying tyramine’s effects. This statement is accurate, as dietary caution is critical to prevent serious adverse reactions.
Choice B reason: MAOIs, like phenelzine, take 2-6 weeks to improve depressive symptoms by increasing monoamine levels (serotonin, norepinephrine, dopamine). Immediate improvement does not occur due to gradual synaptic changes. This statement is inaccurate, as the delayed onset is a key characteristic of MAOIs, similar to other antidepressants.
Choice C reason: MAOIs are reserved for treatment-resistant depression when newer drugs like SSRIs fail, due to their side effect profile and dietary restrictions. They effectively increase monoamine availability but are less preferred due to safety concerns. This statement is accurate, reflecting their role in refractory cases.
Choice D reason: MAOIs can cause hypertensive crisis via drug interactions (e.g., with SSRIs or sympathomimetics), as they inhibit monoamine breakdown, leading to excessive norepinephrine. This can result in severe blood pressure elevation. This statement is accurate, as drug interactions are a significant risk with MAOI therapy.